1. bookVolume 17 (2016): Issue 1 (March 2016)
Journal Details
License
Format
Journal
First Published
30 Mar 2016
Publication timeframe
4 times per year
Languages
English
Copyright
© 2020 Sciendo

Adriamycin - efficacy and possible adverse effects

Published Online: 08 Jun 2016
Page range: 38 - 46
Received: 25 Jan 2016
Accepted: 26 Feb 2016
Journal Details
License
Format
Journal
First Published
30 Mar 2016
Publication timeframe
4 times per year
Languages
English
Copyright
© 2020 Sciendo
Abstract

Adriamycin (doxorubicin) is a chemical substance in the anthracycline class with a wide range of applications in oncology and hematology. The mechanism of action of Adriamycin is related to formation of irregular bonds between nucleobases of DNA and inhibition of key enzymes of DNA synthesis - topoisomerase I and II as well as to formation of free radicals damaging DNA.

A major limitation in the drug use is associated with its adverse effects such as cardiotoxicity and hepatotoxicity.

The mechanism of myocardial injury by Adriamycin is linked to an increase in oxidative stress associated with impaired mitochondrial function and structure.

Cardiotoxicity of anthracyclines is classified as: acute, chronic or late (delayed).

Hepatotoxicity of Adriamycin as a damage of the liver is associated with a dysfunction of this organ. Adriamycin studies have shown increased level of transaminase present in 40% of patients treated with Adriamycin. The state was transient and asymptomatic, returning to the initial level even when treatment continued.

Knowledge of cancer diseases contributed to a successive creation of two improved forms of Adriamycin (doxorubicin) – nonpegylated and pegylated formulas of the drug.

The mechanism of anticancer effects of liposomal Adriamycin is similar to the mechanism of conventional Adriamycin, but placement of the molecules of active substance in liposomes has significant influence on the distribution of the drug.

In order to increase the distribution of the drug, a special form of liposomal Adriamycin has been created by covering the surface of the liposomes with a hydrophilic polymer - (MPEG). This process, known as pegylation, decreases the interactions between the lipid bilayer membrane and the plasma components. Pegylated form of the drug is associated with a higher incidence of acute complications.

Keywords

1. Wallace K.B.: Doxorubicin-induced cardiac mitochondriopathy. Pharmacology & Toxicology 2003; 93:105-115.Search in Google Scholar

2. Denisso T., Kowalski D.M.: Przegląd leków stosowanych w onkologii. W. Krzakowski M. (ed.) Onkologia Kliniczna. Bogris Wydawnictwo Medyczne, Warszawa 2006; 235-244.Search in Google Scholar

3. Gniazdowski M., Szmigiero L.: Molekularne mechanizmy oddzia-ływania związków przeciwnowotworowych na DNA. Na Pograniczu Chemii i Biologii, 2003; 7: 45-73.Search in Google Scholar

4. Kufe D.W., Holland J.F., Frei E.: Cancer Medicine 6., BC Decker, Hamilton 2003.Search in Google Scholar

5. Jarząbek M., Jargiełło T., Janczarek M., Pyra K., Wolski A., Budzyńska A., Szczerbo-Trojanowska M.: Leczenie guzów przerzutowych w wątrobie za pomocą wewnątrznaczyniowej chemoembolizacji z użyciem mikrocząstek nasączonych cytostatykiem (DEMTACE). Wydawnictwo Borgis - Postępy Nauk Medycznych 5/2012;446-450.Search in Google Scholar

6. Polskie Towarzystwo Urologiczne: Zasady postępowania u chorych na raka pęcherza moczowego. Warszawa 2002.Search in Google Scholar

7. Milczek T., Emerich J., Klasa-Mazurkiewicz D.: Chemioterapia dootrzewnowa w leczeniu chorych na raka jajnika. Curr. Gynecol. Oncol. 2009; 7 (4): 270-281.Search in Google Scholar

8. Wcisło G., Korniluk J., Szarlej-Wcisło K., Pawlak W.Z., Nurzyński P., Duchnowska R.: Leczenie chorób nowotworowych czynnikiem martwicy nowotworów – alfa (TNF-alfa). Współczesna Onkologia, 2002; 4: 222–227.Search in Google Scholar

9. Gabizon et al. Pharmacokinetics of Pegylated Liposomal Doxorubicin Review of Animal and Human Studies. Clin Pharmacokinet 2003; 42 (5): 419-436.Search in Google Scholar

10. National Institute for Health and Clinical Excellence; TA91 Ovarian cancer (advanced) - paclitaxel, pegylated liposomal doxorubicin hydro-chloride and topotecan (review): Guidance; 25 May 2005.Search in Google Scholar

11. Gordon AN, Fleagle JT, Guthrie D, Parkin DE, Gore ME, Lacave AJ. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol. 2001;19:3312-3322.Search in Google Scholar

12. Gordon A.N., Tonda M., Sun S., Rackoff W.: Long-term survival advantage for women with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer. Gynecol Oncol. 2004; 95:1-8.Search in Google Scholar

13. Podlewski J.K., Chwalibogowska – Podlewska A.: Leki współczesnej terapii. Medical Tribune Polska, Warszawa 2009; 270-271; 288-289.Search in Google Scholar

14. Dwyer Schull P. (ed.). The oncology drug & regiments. New York. Elsevier Oncology 2006; 128-131; 139-143.Search in Google Scholar

15. Wilkers G.M., Barton-Burke M.: Oncology nursing drug handbook 2010. Jones and Bartlett Publishers. Sadbury 2010; 151-154; 163-168.Search in Google Scholar

16. Deptała A., Omyła-Staszewska J., Staszewska-Skurczyńska M.: Kardiotoksyczność antracyklin i kardioprotekcja. Fakty i mity. Wsp. Onkol. 2004; 8: 107-111.Search in Google Scholar

17. Szmit S., Grabowski M.: Powikłania kardiologiczne leczenia raka piersi. Terapia 2008; 16: 46-55.Search in Google Scholar

18. Szmit S., Główczyńska R., Szczylik C., Opolski G.: Niewydolność serca po chemioterapii. Terapia 2007; 15: 77-87.Search in Google Scholar

19. Wilkers G.M., Barton-Burke M.: Oncology nursing drug handbook 2010. Jones and Bartlett Publishers. Sadbury 2010; 151-154; 163-168.Search in Google Scholar

20. Dwyer Schull P. (ed.). The oncology drug & regiments. New York. Elsevier Oncology 2006; 128-131; 139-143.Search in Google Scholar

21. Navarro V.J, Senior J.R.: Drug-related hepatotoxicity. N Engl J Med. 2006; 354: 731-9.Search in Google Scholar

22. King P.D., Perry M.C.: Hepatotoxicity of chemotherapy. Oncologist 2001; 6: 162-76.Search in Google Scholar

23. Gonzalez F.J., Turkey R.H.: Drug metabolism. In: Brunton L.L., Lazo J.S., Parker K.L., editors. Goodman & Gilmans the pharmacological basis of therapeutics. Eleventh ed. New York, McGraw-Hill: Medical Publishing Division. 2006; 71-91.Search in Google Scholar

24. Gabizon et al.: Pharmacokinetics of Pegylated Liposomal Doxorubicin Review of Animal and Human Studies. Clin Pharmacokinet 2003; 42 (5): 419-436.Search in Google Scholar

25. Gunawan B.K., Kaplowitz N.: Clinical perspectives on xenobiotic-induced hepatotoxicity. Drug Metab Rev 2004; 36: 301-12.Search in Google Scholar

26. Liu Z.X., Kaplowitz N.: Immune-mediated drug-induced liver disease. Clin Liver Dis 2002; 6: 755-74.Search in Google Scholar

27. Gunawan B.K., Kaplowitz N.: Mechanisms of drug-induced liver disease. Clin Liver Dis 2007; 11: 459-75.Search in Google Scholar

28. Hartleb M.: Polekowe uszkodzenia wątroby. Terapia 2008; 16: 67-74.Search in Google Scholar

29. Ma B., Yeo W., Hui P., Ho W.M., Johnson P.J.: Acute toxicity of adjuvant doxorubicin and cyclophosphamide for early breast cancer - a retrospective review of Chinese patients and comparison with an historic Western series. Radiother Oncol 2002; 62: 185-189.Search in Google Scholar

30. Chalasani N., Fontana R.J., Bonkovsky H.L., Watkins P.B., Davern T., Serrano J., Yang H., Rochon J.; Drug Induced Liver Injury Network (DILIN). Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology 2008; 135: 1924-1934.Search in Google Scholar

31. Reuben A., Koch D.G., Lee W.M.; Acute Liver Failure Study Group. Drug-induced acute liver failure: results of a U.S. multicenter, prospective study. Hepatology 2010; 52: 2065-2076.Search in Google Scholar

32. Pieńkowski T. Rak piersi. W: Krzakowski M. (ed.) Onkologia kliniczna. Bogris Wydawnictwo Medyczne, Warszawa 2006; 1014-1056.Search in Google Scholar

33. Waterhouse D.N., Tardi P.G., Mayer L.D. et al.: A comparison of liposomal formulation of doxorubicin with drug administered in free for: changing toxicity profiles. Drug Saf. 2001; 24:903-920.Search in Google Scholar

34. Gabizon A., Catane R., Uziely B. et al.: Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethyleneglycol coated in liposomes. Cancer Res. 1994; 54: 987–992.Search in Google Scholar

35. Rahman A., White G., More N. et al.: Pharmacological, toxicological and therapeutic evaluation in mice of doxorubicin entrapped in cardiolipin liposomes. Cancer Res. 1985; 45: 796–803.Search in Google Scholar

36. Cowens J.W., Creaven P.J., Greco W.R. et al.: Initial clinical (phase I) trial of TLC D–99 (doxorubicin encapsulated in liposomes). Cancer Res. 1993; 53: 2796–802.Search in Google Scholar

37. Safra T., Muggia F., Jeffers S. et al.: Pegylated liposomal doxorubicin (Doxil): reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg/m2. Ann. Oncol. 2000; 11: 1029–1033.Search in Google Scholar

38. O’Brien M.E., Wigler N., Inbar M. et al.: Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (Caelyx/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann. Oncol. 2004; 15: 440–449.Search in Google Scholar

39. Waterhouse D.N., Tardi P.G., Mayer L.D. et al.: A comparison of liposomal formulation of doxorubicin with drug administered in free for: changing toxicity profiles. Drug Saf. 2001; 24: 903–920.Search in Google Scholar

40. Harris L., Batist G., Belt R. et al.: Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma. Cancer 2002; 94: 25–36.Search in Google Scholar

Plan your remote conference with Sciendo